Syapse®,announced a partnership with Illumina, Inc. aimed at assessing the real-world uptake and actionability of comprehensive genomic profiling in the community oncology health system setting. The proliferation of targeted therapies has given many patients hope for a brighter future, but the ability to be tested for and receive those therapies relies upon clinical decision-making. Using the right type of biomarker test, with the right patient, at the right time can ensure that the patient is matched with the therapy most likely to improve their outcomes as early as possible and can potentially eliminate the need for other diagnostic procedures that can be inconvenient, costly, and painful, such as repeat biopsies.

As such, the work between Syapse and Illumina seeks to understand biomarker testing patterns and actionability of test results to inform clinical decision-making in the community health system setting as a first step toward facilitating improved clinical decision making.